Objectives: The oxazolidinone class of antibiotics such as linezolid have a narrow spectrum of activity that targets Gram-positive bacteria. We hypothesized that the poor activity of linezolid in Gram-negative bacteria is in part caused by relatively low intracellular concentration due to efflux.
Introduction
Linezolid is the first member of the oxazolidinone group of compounds, a class of antibiotics that are chemically unrelated to other currently used antibacterial drugs. Oxazolidinones target the 50S subunit of the prokaryotic ribosome and thereby prevent assembly of the initiation complex, which is a different mode of action from that of other inhibitors of protein synthesis such as chloramphenicol and macrolides. Although the ribosomes of Escherichia coli are as susceptible to linezolid as those of Grampositive cocci, linezolid MICs for Gram-negative bacteria are higher than those for Gram-positive cocci and usually lie above the breakpoint for resistance. 1 The activity of efflux pumps in Gram-negative bacteria appears to account for this finding: E. coli with inactivation of AcrAB, probably the most important RND (resistance-nodulation-cell division)-type multicomponent drug efflux pump in this species, is more susceptible to linezolid than cells with an intact AcrAB pump. 2, 3 A small number of nonlytic arylpiperidines have been shown to increase the accumulation of radiolabelled linezolid in wild-type E. coli cells, whereas such an effect was not seen with the putative efflux pump inhibitor phenylalanine-arginyl-b-naphthylamide (PAbN) Although these findings suggest a role for RND-type efflux pumps in the susceptibility of Gram-negative bacteria to linezolid, confirmatory data showing corresponding differences in intracellular linezolid accumulation between Enterobacteriaceae with and without functional RND pump(s) and Grampositive cocci are not available. In the present work, we used a specific HPLC assay to measure the intracellular linezolid concentration in E. coli, E. aerogenes and C. freundii strains with different efflux pump activity. The effects of NMP on the intracellular concentration of this drug were also assessed.
Materials and methods
Bacterial strains E. coli K-12 strains AG100, 3-AG100, 3-AG100MKX, 1-DC14PS and 2-DC14PS as well as E. aerogenes strains EAEP289 and EAEP298
have previously been described (Table 1) . 6, [8] [9] [10] [11] Reference strains of C. freundii (ATCC8090) and E. aerogenes (ATCC13048) were used in mutant selection experiments. After overnight incubation at 37 C in Luria-Bertani broth, cells were harvested and inocula of 10 10 cfu were plated on LB agar containing inhibitory concentrations (2-16 times the MIC) of levofloxacin. Plates were incubated for 24 h at 37 C. Three to six single colonies from each selecting concentration, if available, were purified on fluoroquinolone-supplemented agar plates and examined for antimicrobial susceptibility. We obtained C. freundii mutant 2-CF and E. aerogenes mutant 1-EA that showed a multidrug-resistant (MDR) phenotype not seen in the parental strains. 2-CF overexpressed acrB; 1-EA had an undefined acquired mechanism of MDR, presumably associated with increased efflux pump activity. We constructed CFASII0 by means of inactivation of acrB in 2-CF, using the l-based Red/ET homologous recombination system (Gene Bridges, Dresden, Germany). 12 
Susceptibility testing
Susceptibility to linezolid and ethidium bromide (EtBr) with or without NMP (final concentration, 100 mg/L) was studied by microbroth dilution with an inoculum of 5 · 10 5 cfu/mL and overnight incubation (18 h) at 37 C in LB broth. Quantitative RT-PCR of acrB and acrF
Gene transcription studies were done as described previously with some modification. 7 Cells were grown to mid-logarithmic phase, and RNA was isolated using the RNeasy Kit (Qiagen, Hilden, Germany). RNA samples were treated with DNase (Qiagen) on the column, quantified and stored at -80
C. An amount of 1 mg total RNA was reverse transcribed into cDNA using the iScriptÔ cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) with an incubation of 45 min at 42 C. cDNA was stored at -20 C. PCR was carried out with the LightCycler FastStart DNA Master SYBR Green I (Roche Diagnostics, Germany). Primers were designed with the webtool primer 3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The primer sequences were: E. coli acrB, GAA CAA CTG GCG AGC AAA CT; E. coli acrF, AGT CTG AAA CCG TGG GAA GA; C. freundii acrB, TTA TCC CAA TGG CGT TCT TC; and E. aerogenes acrB, TCG CGT GAA GAA AGT GTA CG.
The 10 mL final volume contained 2.4 mL of MgCl 2 (25 mM), 0.5 mM of each primer, 1 mL of cDNA extract and 1 mL of Lightcycler Mix including FastStart Taq DNA polymerase, reaction buffer, dNTP mix, SYBR Green I dye and 10 mM MgCl 2 . The PCR profile was as follows: denaturation at 95 C for 10 min and 30-40 cycles of 10 s at 95 C, 5 s at 55 C and 10 s at 72 C. Fluorescence was detected at the end of the 72 C segment in the PCR step (single mode). Expression of the housekeeping gene gapA (glyceraldehyde-3-phosphate dehydrogenase, forward primer sequence, CCA GAA CTT TGT TGG AGT AAC C; reverse primer sequence, AGC TTT AGC AGC ACC GGT A), was used as a relative standard. 13 The results of at least two independent RNA extractions were interpreted using the Relative Expression Software Tool (REST). 14 
Whole cell drug accumulation assays
EtBr and pyronin Y accumulation was measured by spectrum fluorometry as described previously. 5, 6 For the estimation of the intracellular concentration of linezolid, cells were grown to logarithmic phase in LB broth at 37 C, washed in 50 mM sodium phosphate buffer (pH 7.0) and resuspended in the same buffer containing 0.4% glucose to an OD 600 of 1.6-1.7. After an incubation of 10 min at 37 C, linezolid was added to a final concentration of 20 mg/L. At timed intervals, 1 mL samples were removed and centrifuged through silicone oil. The pellet was resuspended in 0.1 M glycine hydrochloride (pH 3.0). After overnight incubation at room temperature, samples were centrifuged and the supernatant was frozen until measurement. The HPLC analysis was performed following the method of Ehrlich et al. 15 Column switching was not necessary. In case of interferences with the matrix, the peak identity was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Experiments included measurements after addition of carbonyl cyanide m-chlorophenylhydrazone (CCCP) (300 mM) or NMP (100 mg/L). For selected strains, the NMP concentration was doubled (200 mg/L). All tests were done in triplicate. Staphylococcus aureus ATCC 29123 and Enterococcus faecium ATCC 6057 were included as Gram-positive control strains in the linezolid accumulation assays.
Results and discussion
MICs of linezolid (4-8 mg/L) and EtBr (2-16 mg/L) for effluxdeficient strains E. coli 1-DC14PS, E. aerogenes EAEP298 and C. freundii CFAS0 and CFASII0 were much lower than for wild-type strains or for strains overexpressing an RND-type efflux pump (Table 1) . When NMP was added to either of the two drugs, MICs decreased 4-fold only for efflux-competent strains (Table 1) . MICs in the presence of NMP were in all cases slightly higher than expected from efflux-deficient control strains. Thus, the transport inhibition by NMP at the concentration used was submaximal.
Accumulation data for the two dyes EtBr and pyronin Y and for linezolid are shown in Figures 1 and 2 . Maximal accumulation of the three substances was observed in the efflux-incompetent strains, and lower intracellular concentrations were measured in the other test strains. E. coli wild-type strain AG100 accumulated less of the three substrates than the two other species, but in the case of linezolid and EtBr this did not perfectly correlate with the MICs. However, the relationship between accumulation in effluxcompetent versus efflux-incompetent cells correlated well with the MICs for the test strains of a given species (Figures 1 and 2) .
Addition of NMP and CCCP increased the intracellular concentration of linezolid (Figure 1 ). The increases with NMP were seen only in efflux-competent strains and were smaller than with CCCP, which is consistent with a submaximal effect of NMP, as seen in the MIC reduction assays. Alternatively, CCCP may have inhibited other pumps that depend on the proton-motive force and are able to bind and pump out linezolid, but are not inhibited as well by NMP. This is supported by the observation of linezolid accumulation levels increasing slightly with CCCP, even in efflux-'incompetent' cells. This effect was largest in Enterobacter. It is unknown whether the recently described eefABC efflux system which accommodates macrolides 16 can explain this finding. In AG100 and 3-AG100 we used an NMP concentration of 200 mg/L, which resulted in a large increase (2-fold) in the linezolid accumulation (data not shown), but the levels were still slightly lower than those obtained after CCCP addition.
At an extracellular concentration of 20 mg/L the level of linezolid in the supernatant fluid after cell lysis ranged between 0.21 (E. coli 3-AG100 and 3-AG100MKX) and 0.35 mg/L (C. freundii CF). With the same assay conditions the intracellular linezolid concentration in the two Gram-positive control organisms was higher (0.41 mg/L in both S. aureus and E. faecium). Linezolid levels could be increased by pump inactivation or inhibition to >0.5 mg/L, which is beyond the levels probably typical for S. aureus and enterococci although the MICs did not fall to a level <4-8 mg/L. Thus, the correlation between the intracellular accumulation of and susceptibility to linezolid was not perfect; MICs were 0.5-2 mg/L for Gram-positive control strains. Currently, there is no plausible explanation for this finding. Linezolid, like macrolides and the recently described peptide deformylase inhibitors, has a narrow spectrum of activity, typically including Gram-positive pathogens. The observation that intracellular levels of linezolid could be increased by efflux inhibition to levels higher than those found in the typical target organisms is, we believe, noteworthy. With the increasing understanding of the mechanism of pump action and substrate binding sites it might be possible to design molecules that are less sensitive to efflux and/or that more efficiently inhibit relevant efflux pumps in Gram-negative bacteria. [17] [18] [19] Recycling of existing drugs, including narrow-spectrum drugs, for use in Gram-negative bacterial infections might then be a realistic goal. 
